Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HOB Biotech GroupSHSE:688656 -2.06%83 PB Ratio is 6.12 as of Jul. 24, 2026, which is 34% above its 10-year median of 4.58. GuruFocus rates SHSE:688656 with a GF Score™ of 83/100 and a GF Value™ of ¥89.36 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 786 Medical Devices & Instruments companies, HOB Biotech Group ranks worse than 85.11% on this metric.
HOB Biotech Group Corp Ltd stock PB Ratio (=6.24) is close to 1-year low of 6.24.
The historical rank and industry rank for HOB Biotech Group's PB Ratio or its related term are showing as below:
SHSE:688656'
s PB Ratio Range Over the Past 10 Years
Min: 1.58 Med: 4.58 Max: 20.86
Current: 6.11
During the past 10 years, HOB Biotech Group's highest PB Ratio was 20.86. The lowest was 1.58. And the median was 4.58.
SHSE:688656's PB Ratio is ranked worse than 85.11% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 2.02
vs SHSE:688656: 6.11
During the past 12 months, HOB Biotech Group's average Book Value Per Share Growth Rate was 0.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 17.40% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of HOB Biotech Group was 63.10% per year. The lowest was 1.50% per year. And the median was 35.90% per year.
Back to Basics: PB Ratio
HOB Biotech Group (SHSE:688656) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
HOB Biotech Group PB Ratio Related Terms
HOB Biotech Group PB Ratio Historical Data
* Premium members only.
The historical data trend for HOB Biotech Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, HOB Biotech Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOB Biotech Group PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HOB Biotech Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where HOB Biotech Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
HOB Biotech Group (SHSE:688656) has a PB Ratio of 6.12 as of Jul. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on HOB Biotech Group and its competitors. This is 34% above median its historical median of 4.58. Over the past decade, HOB Biotech Group's PB Ratio has ranged from 1.58 to 20.86. According to the industry distribution chart, HOB Biotech Group ranks #669 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 85.1%.
Is HOB Biotech Group's PB Ratio too high?
HOB Biotech Group's current PB Ratio of 6.12 is 34% above median its 10-year median of 4.58. Over the past 10 years, this metric has ranged from a low of 1.58 to a high of 20.86. The Medical Devices & Instruments industry median PB Ratio is 2.02. HOB Biotech Group's value of 6.12 is 203% above this industry median. Based on the distribution chart, HOB Biotech Group ranks #669 out of 786 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, HOB Biotech Group has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HOB Biotech Group's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HOB Biotech Group ranks #669 out of 786 companies for PB Ratio. This places HOB Biotech Group in the lower half of its industry. The industry median PB Ratio is 2.02. HOB Biotech Group's value of 6.12 is 203% above this benchmark. Historically, HOB Biotech Group's own PB Ratio has ranged from 1.58 to 20.86 over the past decade. While the company's 10-year median is 4.58 vs. the industry median of 2.02, HOB Biotech Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOB Biotech Group's current PB Ratio of 6.12 is 203% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on HOB Biotech Group and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOB Biotech Group's current PB Ratio is 6.12, which is 34% above median its own 10-year median of 4.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOB Biotech Group stock overvalued right now?
Based on GuruFocus' analysis, HOB Biotech Group (SHSE:688656) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥89.36, compared to a current price of ¥79.59 — trading 10.9% below its estimated fair value. The current PB Ratio is 6.12, which is 34% above median its 10-year median of 4.58 and 203% above the Medical Devices & Instruments industry median of 2.02. HOB Biotech Group's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For HOB Biotech Group (SHSE:688656), the current PB Ratio is 6.12 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOB Biotech Group (SHSE:688656) Overvalued in 2026?
Based on GuruFocus' analysis, HOB Biotech Group stock appears to be undervalued.
The current stock price of ¥79.59 is trading 10.9% below its estimated GF Value™ of ¥89.36.
GuruFocus considers HOB Biotech Group to be Modestly Undervalued.
Key valuation signals for SHSE:688656:
PB Ratio: 6.12 (34% above median its 10-year median of 4.58)
GF Value™: ¥89.36 vs. price of ¥79.59 (10.9% below fair value)
Industry Position: 203% above the Medical Devices & Instruments median (#669 of 786)
No single metric tells the full story. See the SHSE:688656 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOB Biotech Group Corp Ltd is an in vitro diagnostic company. The firm is specialized in providing diagnostic tools to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care.
83GF Score
Get the complete analysis for SHSE:688656
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688656 has been successfully added to your 
